30 results
424B3
CTCX
Carmell Corp - Ordinary Shares
5 Jun 24
Prospectus supplement
6:06am
regulatory approval of marketing claims for the uses that we are developing;
establishment and demonstration of the advantages, safety and efficacy … that could harm our reputation, business, financial condition and results of operations.
The discovery of serious safety issues with our products
8-K
EX-99.1
CTCX
Carmell Corp - Ordinary Shares
1 Apr 24
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
4:47pm
banks. The technology underpinning the Carmell SecretomeTM has been extensively tested for safety and efficacy, significantly surpassing standards set
8-K
EX-99.1
e4008 lkc
25 Mar 24
Entry into a Material Definitive Agreement
8:46pm
8-K
EX-10.1
tqopdgi
25 Mar 24
Entry into a Material Definitive Agreement
8:46pm
8-K/A
EX-99.1
1x2tueqakjuno8
16 Jan 24
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
6:51pm
8-K
EX-99.1
byf4zb096 xbalxr
16 Jan 24
Carmell Corp Announces Addition of Dr. Jason D. Bloom to Scientific Advisory Board
6:01pm
8-K
EX-10.1
2l27iw3
1 Aug 23
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
4:39pm
425
er63nf4i93aimyk5 xz
6 Jul 23
Business combination disclosure
5:15pm
8-K
EX-99.1
v47u1 5y8
6 Jul 23
Other Events
5:11pm
424B3
bz92qtee
23 Jun 23
Prospectus supplement
4:47pm